Anthera Pharmaceuticals Inc (ANTH) financial statements (2020 and earlier)

Company profile

Business Address 25801 INDUSTRIAL BOULEVARD, SUITE B
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2018
TTM
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 2214732625
Cash and cash equivalents 2214732619
Short-term investments      5
Receivables   0   
Prepaid expense and other current assets0
Other undisclosed current assets 12100 
Total current assets: 3234832625
Noncurrent Assets
Property, plant and equipment 010011
Regulated entity, other noncurrent assets      0
Restricted cash and investments     10 
Other noncurrent assets     0
Total noncurrent assets: 0100111
TOTAL ASSETS: 4234833726
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 377446
Accounts payable 255245
Accrued liabilities 100000
Employee-related liabilities 022100
Debt     39
Deferred revenue and credits  0   
Other liabilities    1  
Other undisclosed current liabilities 241103
Total current liabilities: 51186819
Noncurrent Liabilities
Long-term debt and lease obligation     1511
Long-term debt, excluding current maturities     1511
Liabilities, other than long-term debt 4     
Other liabilities 4     
Total noncurrent liabilities: 4   1511
Total liabilities: 911862330
Stockholders' equity
Stockholders' equity attributable to parent, including: (5)1240(2)15(4)
Common stock 000000
Additional paid in capital 429411392315302257
Accumulated other comprehensive loss      (0)
Accumulated deficit (434)(408)(352)(317)  
Other undisclosed stockholders' equity attributable to parent 09  (287)(260)
Other undisclosed stockholders' equity  0    
Total stockholders' equity: (5)1340(2)15(4)
TOTAL LIABILITIES AND EQUITY: 4234833726

Income statement (P&L) ($ in millions)

3/31/2018
TTM
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Gross profit:  03  0
Operating expenses (36)(57)(38)(28)(28)(56)
Other undisclosed operating loss      (0)
Operating loss: (36)(57)(35)(28)(28)(56)
Nonoperating income (expense) 1020 (3)(3)
Other nonoperating income (expense) (0)(0)0   
Interest and debt expense    (1)(3)(3)
Net loss: (27)(56)(35)(30)(33)(63)
Other undisclosed net income (loss) attributable to parent    (0)33
Net loss attributable to parent: (27)(56)(35)(30)(31)(59)
Other undisclosed net loss available to common stockholders, basic (3)(11)    
Net loss available to common stockholders, diluted: (29)(66)(35)(30)(31)(59)

Comprehensive Income ($ in millions)

3/31/2018
TTM
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (27)(56)(35)(30)(33)(63)
Comprehensive loss: (27)(56)(35)(30)(33)(63)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (0)33
Comprehensive loss, net of tax, attributable to parent: (27)(56)(35)(30)(31)(59)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: